Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-20-030140
Filing Date
2020-11-02
Accepted
2020-11-02 20:54:20
Documents
2
Period of Report
2020-10-27

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1578
2 EX-24 DOCUMENT attachment1.htm EX-24 4677
  Complete submission text file 0000899243-20-030140.txt   7782
Mailing Address 131 DARTMOUTH STREET SUITE 502 BOSTON MA 02116
Business Address 131 DARTMOUTH STREET SUITE 502 BOSTON MA 02116 844-304-2048
Cerevel Therapeutics Holdings, Inc. (Issuer) CIK: 0001805387 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O CEREVEL THERAPEUTICS HOLDINGS, INC. 51 ASTOR PLACE, 10TH FLOOR NEW YORK NY 10003
Business Address
Birnbaum Morris (Reporting) CIK: 0001830912 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39311 | Film No.: 201281730